Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction

被引:5
|
作者
Ahn, Sun Tae [1 ]
Lee, Dong Hyun [1 ]
Jeong, Hyeong Guk [1 ]
Kim, Jong Wook [1 ]
Oh, Mi Mi [1 ]
Park, Hong Seok [1 ]
Moon, Du Geon [1 ]
机构
[1] Korea Univ, Dept Urol, Guro Hosp, 148 Gurodong Ro, Seoul 08308, South Korea
关键词
Fixed-dose; Medication persistence; Tadalafil; Tamsulosin; URINARY-TRACT SYMPTOMS; OVERACTIVE BLADDER; MEN; THERAPY; SAFETY; EFFICACY;
D O I
10.4111/icu.2020.61.1.81
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The primary aim of this study was to assess treatment persistence with a fixed-dose combination (FDC) of tadalafil (5 mg) and tamsulosin (0.4 mg). This study also evaluated the reasons for early treatment discontinuation. Materials and Methods: This retrospective observational study included patients with benign prostatic hyperplasia and erectile dysfunction who started an FDC treatment of tadalafil (5 mg) and tamsulosin (0.4 mg) between July 2017 and February 2018. Treatment persistence and reasons for early discontinuation were evaluated during the first 6 months. The cumulative discontinuation rate and differences in various parameters were assessed using Kaplan-Meier analysis and the log-rank test, respectively. Factors related to persistence were analyzed using a Cox proportional hazard model. Results: Overall, 97 patients were included in the study. The cumulative persistence rate at 30, 90, and 180 days was 88.7%, 66.0%, and 54.6%, respectively. The cumulative persistence over 6 months differed significantly according to the administration of FDC therapy (log-rank p=0.005) and age (log-rank p=0.024). Younger patients (odds ratio, 2.049; p=0.021) and treatment-naive patients (odds ratio, 2.461; p=0.006) were more likely to discontinue therapy within 6 months. The common reasons for discontinuing therapy were side effects (63.6%) and perceived poor efficacy (22.7%). Conclusions: Side effects were reported to be the main reason for treatment discontinuation. Thus, to improve compliance for a once-daily FDC of tadalafil (5 mg) and tamsulosin (0.4 mg), it is recommended to select patients who show adaptation to a combination of a-blockers and phosphodiesterase type 5 inhibitors prior to FDC treatment.
引用
收藏
页码:81 / 87
页数:7
相关论文
共 50 条
  • [41] Re: Dutasteride plus Tamsulosin Fixed-Dose Combination First-Line Therapy versus Tamsulosin Monotherapy in the Treatment of Benign Prostatic Hyperplasia: A Budget Impact Analysis in the Greek Healthcare Setting Editorial Comment
    Kashyap, M.
    Belleville, S.
    Mulsant, B. H.
    Hilmer, S. Nl
    Paquette, A.
    Tu, L. M.
    Tannenbaum, C.
    JOURNAL OF UROLOGY, 2015, 194 (05): : 1354 - 1355
  • [42] Treatment satisfaction in men using flexible-dose versus 100-mg fixed-dose sildenafil citrate for erectile dysfunction
    Stecher, V.
    Mulhall, J.
    Tseng, L. -J.
    JOURNAL OF SEXUAL MEDICINE, 2008, 5 : 116 - 117
  • [43] THE DAILY THERAPY WITH L-ARGININE 2500 MG AND TADALAFIL 5 MG IN COMBINATION AND IN MONOTHERAPY FOR THE TREATMENT OF ERECTILE DYSFUNCTION: A PROSPECTIVE, RANDOMIZED MULTICENTRE STUDY
    Gallo, L.
    Pecoraro, S.
    Sarnacchiaro, P.
    Silvani, M.
    Antonini, G.
    JOURNAL OF SEXUAL MEDICINE, 2020, 17 (06): : S133 - S133
  • [44] IMPROVEMENT OF INSULIN RESISTANCE AND ENDOTHELIAL FUNCTION IN PATIENTS WITH ERECTILE DYSFUNCTION BY ONCE A DAY TREATMENT WITH TADALAFIL 5 MG
    Kim, S. C.
    Park, S. J.
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 : 160 - 160
  • [45] Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction
    Cui, H.
    Liu, B.
    Song, Z.
    Fang, J.
    Deng, Y.
    Zhang, S.
    Wang, H.
    Wang, Z.
    ANDROLOGIA, 2015, 47 (01) : 20 - 24
  • [46] Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial
    Kim, Sae Woong
    Park, Nam Cheol
    Lee, Seung Wook
    Yang, Dae Yul
    Park, Jong Kwan
    Moon, Du Geon
    Yang, Sang-Kuk
    Lee, Sung Won
    Moon, Ki Hak
    Ahn, Tai Young
    Kim, Soo Woong
    Park, Kwangsung
    Min, Kweon Sik
    Ryu, Ji-Kan
    Son, Hankil
    Jung, Jina
    Hyun, Jae Seog
    JOURNAL OF SEXUAL MEDICINE, 2017, 14 (08): : 1018 - 1027
  • [47] PHARMACOECONOMIC ANALYSIS OF USING SOLIFENACIN AND MODIFIED-RELEASE TAMSULOSIN FIXED DOSE COMBINATION FOR TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
    Avxentyev, N.
    Frolov, M.
    VALUE IN HEALTH, 2017, 20 (09) : A488 - A489
  • [48] PHARMACOKINETIC COMPARISON OF A SINGLE ORAL DOSE OF JLP-1207, A FIXED-DOSE COMBINATION OF SOLIFENACIN 5MG AND TAMSULOSIN 0.2MG, AND CO-ADMINISTRATION OF INDIVIDUAL TABLETS
    Jeon, I.
    Moon, S.
    Choi, Y.
    Hwang, I.
    Kim, J.
    Lee, Y.
    Yoon, S.
    Cho, J-Y
    Yu, K-S
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S68 - S68
  • [49] Whether Adding Vitamin D to Tadalafil 5 mg Treatment Is Useful in Patients with Erectile Dysfunction and Vitamin D Deficiency?
    Demirci, Aykut
    Cakan, Murat
    Topcuoglu, Murat
    UROLOGIA INTERNATIONALIS, 2021, 105 (5-6) : 514 - 519
  • [50] The efficacy and safety of combination of injectable testosterone undecanoate and once-daily dose of tadalafil 5mg in the treatment of erectile dysfunction with testosterone deficiency syndrome
    Park, M. G.
    Yeo, J. K.
    Cho, D. Y.
    Park, S. S.
    Kang, K. S.
    Oh, M. M.
    Bae, J. H.
    Moon, D. G.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E703 - U498